In the present study—the largest to our knowledge—we have analyzed the RNA-seq data of 3217 primary breast tumors for ESR1 resistance mutations and, for the first time, identify the association of such mutations to clinical outcomes in the adjuvant treatment setting. Here, ESR1 is linked to breast neoplasm.